Comparison of intravenous hydralazine and intravenous labetalol in the management of severe hypertensive disorders of pregnancy: a tertiary care centre study

Authors

  • Manvi Verma Department of Obstetrics and Gynecology, SMGS Hospital, GMC Jammu, Jammu and Kashmir, India
  • Shashi Gupta Department of Obstetrics and Gynecology, SMGS Hospital, GMC Jammu, Jammu and Kashmir, India
  • B. R. Bhagat Department of Obstetrics and Gynecology, SMGS Hospital, GMC Jammu, Jammu and Kashmir, India
  • Aakanksha Mahajan Department of Obstetrics and Gynecology, SMGS Hospital, GMC Jammu, Jammu and Kashmir, India
  • Baseerat Kaur Department of Obstetrics and Gynecology, SMGS Hospital, GMC Jammu, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20182330

Keywords:

Hydralazine, Hypertensive disorders of pregnancy, Labetalol

Abstract

Background: Severe hypertension in pregnancy (SBP ≥160 mmHg &/or DBP ≥ 110 mmHg) must be treated judiciously to prevent maternal and fetal complications. The study was conducted to compare the efficacy, adverse effects, maternal and fetal outcome between Hydralazine and Labetalol which are the most commonly used drugs for the purpose.

Methods: In a prospective study, 130 pregnant patients each with severe hypertension presenting to SMGS Hospital Jammu were randomized in 2 groups and administered hydralazine or labetalol intravenously. The efficacy of the two drugs was measured in terms of number of doses required to obtain target BP and the timing to achieve the same. The incidence of adverse effects, maternal and fetal outcomes were also compared. Comparisons among the two groups was performed by using independent Student’s t test for normally distributed variables, Fishers’ exact test, and Pearson Chi Square test for categorical variables. The level of significance was set at p<0.05 for all analysis.

Results: There was no statistical difference between the two drugs in terms of efficacy. Significantly more low-birth weight infants were born in the hydralazine group. Also, the adverse effects were significantly more in the hydralazine group.

Conclusions: Both hydralazine and labetalol can be used to treat hypertensive emergencies of pregnancy but hydralazine is associated with more side effects.

References

ACKNOWLEDGMENTS

Authors would like to thank all patients for their cooperation.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

Cunningham, Leveno, Bloom, Spong, Dashe, Hoffman, Casey, Sheffield , eds. Hypertensive disorders in : Williams Obstetrics, McGraw-Hill education. 24ed. USA; 2014: 728-761.

Singh BW, Misra R. Hypertensive Disorders. In: Misra R, ed. Ian Donald’s Practical Obstetric Problems, 7 ed, vol. 8. Wolters Kluwer Pvt Ltd; 2014; 142-175.

Neto CN, de Souza AS, Amorim MM. Pre-eclampsia treatment According to scientific evidence. J obstet Gynecol Rev Bras Gynecol Obstet. 2010;32(9):459-68.

Araoye MO. Research Methodology with Statistics for Health and Social Sciences. Nathadex Publishers Ilorin; 2003: 115-129.

Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy (Review). Cochrane Lib. 2007;4:1–78.

Tabasi Z, Oghbaee N, Samimi M, Sadat Z. Comparison between Effects of Intravenous Labetalol and Hydralazine on Control of Hypertension and Maternal and Neonatal Outcomes in Severe Preeclamptic Patients: A Randomized Clinical Trial. Qom Univ Med Sci J. 2012;6(4):44-9.

Delgado De Pasquale S, Velarde R, Rayes O, De La Ossa K. Hydrallazine vs Labetalol for the treatment of severe hypertensive disorders of pregnancy; A randomised controlled trial. Pregnancy Hypertens. 2014;4(1):19–22.

Nombur LI, Agida ET, Isah AY, Ekele BA. A comparison of Hydrallazine and Labetalol in the management of severe pre eclampsia. J Women Health care. 2014;3:6.

Deka Nabanita, Das Gokul Chandra, Baishya Swagata, Yadav Sangeeta. A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension. Sch J App Med Sci. 2016;4(611B):3996-9.

Khan A, Hafeez S, Nasrullah FD. Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy. Pak J Med Sci. 2017;33(2):466–70.

Mable WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70:328–33.

Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J. 1987;71:354–6.

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT. Severe hypertension in pregnancy:hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128:157–62.

Magee LA, Cham C, Waterman EJ, Ohlsson A, Dadelszen PV. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–60.

Downloads

Published

2018-05-26

Issue

Section

Original Research Articles